WVE Wave Life Sciences, Inc.

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...

WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.

Moby summary of Wave Life Sciences Ltd.'s Q2 2026 earnings call

WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026. The company reported second-quarter revenue of $2.3 million, down

WAVE Life Sciences reports robust data for obesity candidate WVE-007 and AATD therapy WVE-006, while navigating a wider net loss and declining revenue.

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue totaled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis

Wave Life Sciences has seen its share price fall 64.0% year to date, yet the valuation checks suggest the stock still screens as expensive rather than a clear bargain. Wave Life Sciences is down 64.0% year to date, which puts the recent slide front and center for anyone weighing the current valuation. Future progress on its drug pipeline can support the case for the current price, while uncertainty around the timing and reliability of cash flows remains a key risk for how much investors are...

Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.